LOGIN  |  REGISTER
FILTER BY TOPIC:     Enrollment   Pre-Clinical   First Dose   Phase 1   Phase 1/2   Phase 2   Phase 2/3   Phase 3  

Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025

April 25
Last Trade: 4.50 0.42 10.29

Positive IND-enabling data on MP0712 targeting DLL3, the most advanced Radio-DARPin program in co-development with Orano Med, entering clinical development in 2025 First preclinical data of novel targeted Radio-DARPin against mesothelin (MSLN), in co-development with Orano...Read more


Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept...

April 25
Last Trade: 1.06 -0.03 -2.75

Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene expression analysis of PDX responders/non-responders Mouse analog of MICVO in a syngeneic model indicated strong activity...Read more


ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care...

April 25
Last Trade: 0.54 -0.06 -9.82

Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology’s investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R2) was well-tolerated and demonstrated promising anti-tumor activity Combination generated complete responses...Read more


VYNE Therapeutics Provides Update on VYN202 Program

April 25
Last Trade: 1.45 -0.43 -22.87

BRIDGEWATER, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) verbally informed the Company that it placed a clinical hold on the Company’s Phase 1b study evaluating VYN202 for...Read more


AbbVie Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE (TrenibotE) for the Treatment of...

April 24
Last Trade: 186.47 -17.61 -8.63

TrenibotE is a first-in-class botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8 hours after administration (earliest assessment time) and shorter duration of effect of 2-3 weeks.  If approved, TrenibotE will be the first neurotoxin of its kind...Read more


Equillium Announces Feedback from the U.S. Food and Drug Administration

April 24
Last Trade: 0.44 -0.03 -6.81

LA JOLLA, Calif. / Apr 24, 2025 / Business Wire / Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that the company has received...Read more


Featured Stock

Assertio

Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through...

CLICK TO LEARN MORE

Biggest Gainers

 
CompanyChangeLast Trade
Eli Lilly 24.85 2.89 $884.58
argenx 14.25 2.37 $614.76
Encompass Health 11.96 11.79 $113.37
Chemed 8.96 1.64 $555.74
Alnylam Pharmaceuticals 8.95 3.69 $251.56
Madrigal Pharmaceuticals 6.86 2.14 $326.79
Aclarion 6.76 901.33 $7.51
McKesson 6.57 0.95 $695.00
Intuitive 6.46 1.27 $514.59
Stryker 4.01 1.11 $365.06
West Pharmaceutical 3.96 1.88 $214.55
Ascendis Pharma 3.70 2.31 $164.15
Merck 2.90 3.63 $82.74
Regeneron Pharmaceuticals 2.88 0.48 $602.64
OpGen 2.87 151.05 $4.77
Jaguar Health 2.84 35.24 $10.90
Addus HomeCare 2.54 2.59 $100.58
Semler Scientific 2.40 6.97 $36.84

Highest Volume

 
CompanyVolumeLast Trade
Sharps Technology 74,222,588 $0.02
Azitra 42,561,658 $0.31
China SXT Pharmaceuticals 37,822,363 $2.37
Pfizer 34,342,718 $22.92
Merck 27,387,547 $82.74
Summit Therapeutics 24,375,957 $23.17
Acrivon Therapeutics 15,994,031 $1.64
Bristol-Myers Squibb 15,963,969 $47.90
Gilead Sciences 14,007,265 $103.17
Insmed 13,585,902 $69.69
Novavax 13,014,900 $6.67
Recursion 12,600,429 $5.69
Iovance Biotherapeutics 12,413,776 $3.51
AbbVie 10,352,092 $186.47
PacBio 9,662,403 $1.11
Viatris 9,097,427 $8.13
UnitedHealth 9,010,635 $418.98
Tempus AI 8,942,642 $52.87
Centene 8,408,467 $57.44
  • Upcoming FDA Catalysts

    • Abeona Therapeutics (NASDAQ: ABEO) PDUFA Date

      April 29, 2025
    • Arcutis Biotherapeutics (NASDAQ: ARQT) PDUFA Date

      May 22, 2025
    • UroGen Pharma (NASDAQ: URGN) PDUFA Date

      June 13, 2025
    • KalVista Pharmaceuticals (NASDAQ: KALV) PDUFA Date

      June 17, 2025
    • Merck (NYSE: MRK) PDUFA Date

      June 23, 2025
    • Regeneron Pharmaceuticals (NASDAQ: REGN) PDUFA Date

      July 10, 2025

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including a small-molecule GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...

CLICK TO LEARN MORE

Invest In Early-Stage Biotech Opportunities

  • Explore venture capital investment opportunities in the healthcare industry and gain direct access to deal flows

  • Private placement shares can generally be purchased at a discount to market prices and have purchase warrants attached to them

  • If the underlying share price rises, warrants can be exercised to further build positions and enhance gains

  • Sign up to receive notifications of future early-stage investment opportunities: